---
title: "杭州九源基因生物醫藥股份有限公司 (02566.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/02566.HK.md"
symbol: "02566.HK"
name: "杭州九源基因生物醫藥股份有限公司"
industry: "生物技術"
---

# 杭州九源基因生物醫藥股份有限公司 (02566.HK)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 港股市場 |
| Website | [www.china-gene.com](https://www.china-gene.com) |

## Company Profile

杭州九源基因工程有限公司是一家主要從事基因藥物研發的中國公司。公司主營業務為生物製藥及相關醫療器械的研發、生產和銷售。公司的主要產品包括骨修復材料、仿製依諾肝素鈉、人粒細胞刺激因子和注射用白細胞介素。公司產品主要用於治療骨科、腫瘤和血液病。公司主要在國內和海外市場開展業務。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:11.000Z

**Overall: B (0.34)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 11 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -1.42% |  |
| Net Profit YoY | -4.00% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.32 |  |
| Dividend Ratio | 0.65% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.31B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.42B |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 9.48% | B |
| Profit Margin | 9.45% | B |
| Gross Margin | 82.22% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -1.42% | D |
| Net Profit YoY | -4.00% | C |
| Total Assets YoY | 44.68% | A |
| Net Assets YoY | 61.68% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1057.79% | B |
| OCF YoY | -1.42% | D |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.75 | B |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 21.73% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 杭州九源基因生物醫藥股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "9.48%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "9.45%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "82.22%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-1.42%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.00%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "44.68%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "61.68%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1057.79%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-1.42%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.75",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "21.73%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百濟神州 (HK.6160) | C | A | B | C | A | B |
| 02 | 信達生物 (HK.1801) | B | A | C | B | A | B |
| 03 | 三生制藥 (HK.1530) | A | B | C | A | C | B |
| 04 | 百奧賽圖-B (HK.2315) | A | A | C | D | B | B |
| 05 | 和鉑醫藥-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 17.10 | 4/70 | 17.93 | 14.38 | 11.22 |
| PB | 1.32 | 6/70 | 1.57 | 1.28 | 1.00 |
| PS (TTM) | 1.62 | 4/70 | 1.74 | 1.38 | 1.12 |
| Dividend Yield | 0.65% | 5/70 | 0.77% | 0.65% | 0.51% |

## References

- [Company Overview](https://longbridge.com/en/quote/02566.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/02566.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/02566.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.